Graft-versus-host disease (GVHD) is the major cause of nonrelapse morbidity and mortality after allogeneic stem cell transplantation (allo-SCT). Prevention and treatment of GVHD remain inadequate and commonly lead to end-organ dysfunction and opportunistic infection. The role of interleukin (IL)-17 and IL-22 in GVHD remains uncertain, due to an apparent lack of lineage fidelity and variable and contextually determined protective and pathogenic effects. We demonstrate that donor T cellderived IL-22 significantly exacerbates cutaneous chronic GVHD and that IL-22 is pro- 
| INTRODUCTION
A significant and increasing proportion (10-15%) of patients with hematologic cancers undergo stem cell transplantation (SCT), as it remains an important curative therapeutic option. The success of allogeneic SCT (allo-SCT) is limited by the development of graft-versus-host disease (GVHD) whereby donor T cells mount an immune response to disparate recipient alloantigens expressed within host tissues. GVHD can manifest acutely or chronically, resulting in significant and widespread tissue damage occurring primarily within the gastrointestinal tract, skin, lung, and liver. 1 Despite advances in immunosuppressive therapies, the incidence of GVHD remains high (>50%). 2, 3 Cutaneous manifestations, including lichenoid and sclerodermatous GVHD, are common late after allo-SCT, with limited treatment options beyond protracted steroid therapy. [3] [4] [5] Chronic GVHD, thus, has a significant detrimental impact on patient quality of life, 3 and new therapeutic strategies are urgently needed.
Donor T cells play a central role in GVHD; depletion of T cells from the donor graft prevents GVHD but is associated with increased rates of relapse and infective complications, which negate any beneficial effect. 6 Cytokines are critical mediators of inflammatory processes after allo-SCT, and interleukin (IL)-22 has been shown to play a particularly complex role in GVHD. 7 IL-22 is a member of the IL-10 cytokine superfamily expressed by both the adaptive (CD4 + and CD8 + T cells) and innate immune system (γδ T, natural killer [NK]T, and innate lymphoid cells [ILCs] , including NK cells, ILC3, and lymphoid tissue inducer cells).
8-10
The IL-22 receptor shares 1 subunit with the IL-10 receptor (IL-10RB2), which forms a heterodimer with the IL-22Rα subunit, expressed almost exclusively by nonhematopoietic tissue. 9, 10 The IL-22Rα is expressed in epithelia, keratinocytes, and fibroblasts such that IL-22 provides an important conduit between the immune system and organ surfaces during infection and tissue injury. 8, 9 In adaptive immunity, IL-22 is often linked with IL-17 expression and indeed is commonly considered as a "Th17"
cytokine. However, more recent studies have demonstrated IL-22 expression independent of IL-17 in multiple contexts and Th22 cells are increasingly recognized as a distinct T cell differentiation program.
11-14
Recipient-derived IL-22, produced by ILCs, promotes the survival and persistence of intestinal stem cells and helps maintain gut epithelial integrity. 15 In contrast, others have demonstrated a pathogenic role for donor T cell-derived IL-22 in murine models of acute GVHD and have shown that donor IL-22 does not contribute to graftversus-leukemia effects. 16, 17 Given that clinical trials using IL-22-Fc are under way to treat acute gastrointestinal GVHD (ClinicalTrials.gov, NCT02406651), 18 the potential pathogenic effects of IL-22 suggest that a better understanding of the cell lineages involved and their clinical relevance is urgently required. Here, we have evaluated the function of IL-22 in the pathophysiology of classic and inflammatory chronic GVHD using preclinical models and patient samples. 
| METHODS

| Mice
| Cell preparation for transplantation
For murine stem cell mobilized grafts, recombinant human granulocytecolony stimulating factor (G-CSF) was given subcutaneously to donors at 10 μg per dose per animal (4-6 days), 20 and splenocytes subsequently isolated for transplantation. T cell depletion was performed by treatment with anti-CD4 (RL172.4), anti-CD8 (TIB211), and antiThy1.2 (HO-13-4), followed by rabbit complement. 21 Cell suspensions contained <1% viable CD3 + T cells. For bone marrow (BM) transplantation, donor T cell-depleted (TCD) BM cells were isolated as described patients with GVHD after allo-SCT. Together, these data demonstrate a key role for donor-derived IL-22 in patients with chronic skin GVHD and confirm parallel but symbiotic developmental pathways of Th22 and Th17 differentiation.
K E Y W O R D S
basic (laboratory) research/science, bone marrow/hematopoietic stem cell transplantation, bronchiolitis obliterans (BOS), cytokines/cytokine receptors, graft-versus-host disease (GVHD), immunobiology, lymphocyte biology: differentiation/maturation, T cell biology previously. 22, 23 Total T cells were isolated by using T cell columns (Cedarlane Laboratories). After column purification, the sample was antibody depleted by using anti-mouse B220 and anti-mouse CD25 conjugated with phycoerythrin (PE) (eBioscience), and magnetic bead isolation was performed by using anti-PE beads (Miltenyi Biotec).
23
For in vitro Th17 differentiation, naive CD4 + T cells were isolated from WT.B6 spleens by using CD4 + columns (Cedarlane Laboratories)
followed by sort purification (CD4
were stimulated with plate-bound anti-CD3 (3 μg/mL; eBioscience) and anti-CD28 (5 μg/mL; eBioscience) in the presence of transforming growth factor (TGF)-β (2 ng/mL; Peprotech), IL-6 (30 ng/mL; Peprotech), tumor necrosis factor (TNF)-α (20 ng/mL, Peprotech), IL-1β
(10 ng/mL; Peprotech), anti-IL-2 antibody (10 μg/mL; BioXCell), and anti-interferon (IFN)γ (10 μg/mL; BioXCell) for 2 days. On day 3, cells were replenished with the same cytokines and antibodies and cultured for an additional 2 days. On day 5, cells were replated into low-cluster 24-well plates in the presence of TGF-β1 (2 ng/mL), IL-6 (25 ng/mL), anti-IL-2 (10 μg/mL), and anti-IFNγ (10 μg/mL) for 2 days. Cells were restimulated on day 7 with plate-bound anti-CD3 and anti-CD28 mAbs with TGF-β (2 ng/mL), IL-6 (30 ng/mL), TNF-α (20 ng/mL), IL-1β
(10 ng/mL), anti-IL-2 (10 μg/mL), anti-IFNγ (10 μg/mL), and IL-23 (R&D Systems) (15 ng/mL). On day 9, cells were again removed from CD3 and CD28 stimulation and cultured in low cluster 24-well plates in the presence of 2 ng/mL TGF-β1, 30 ng/mL IL-6, 20 ng/mL TNF-α, 10 ng/mL IL-1β, 10 μg/mL anti-IL-2, 10 μg/mL anti-IFNγ, and 15 ng/mL IL-23. On day 10, cells were refed with 2 ng/mL TGF-β1, 25 ng/mL IL-6, 15 ng/mL IL-23, 10 ng/mL IL-1β, 10 μg/mL anti-IL-2, and 10 μg/mL anti-IFNγ. On day 12, IL-17 cytokine was assessed by stimulating 1 × 10 7 cells with 50 ng/mL phorbol 12-myristate 13-acetate (PMA), 500 ng/mL ionomycin, and 3 μg/mL Brefeldin A (Sigma-Aldrich) for 6 hours.
| SCT
For murine stem cell-mobilized grafts, B6D2F1 recipients received 10 × 10 6 G-CSF-treated B6-derived splenocytes (day 0) after 1100-cGy total body irradiation (TBI) split over 2 doses (day -1). B6 recipients re- 
| GVHD monitoring and pulmonary function tests
In all in vivo transplant systems, mice were regularly monitored and weights were recorded each week. For pulmonary function assessment, anesthetized mice were weighed, unblinded animals were intubated, and lung function assessed with whole body plethysmography by using the Flexivent system (SCIREQ) and analyzed by using the Flexivent software (version 7.3). B6 and B6D2F1 recipients of G-CSF-mobilized grafts were monitored daily and systemic overall GVHD was assessed weekly by using an established cumulative scoring system, 24 for which the cutaneous GVHD component is scored as 0 if normal, 0.5 for scaling of paws/tail/ears, 1 for areas of alopecia or skin thickening, and 2 for obvious ulceration or areas of denuded skin. B6D2F1 recipients of in vitro polarized T cells were scored at least twice a week for GVHD symptoms using an established cumulative scoring system, 25 in which the cutaneous GVHD score was 0 for no ulcers or alopecia, 1 for skin ulcers with alopecia <1 cm 2 in area, 2 for 1-to 2-cm 2 area of alopecia, 3 for >2-cm 2 area of alopecia; an additional score of 0.3 was added if mice had ulcers or scaling on the paws, tail, or ears.
| Patients
Punch biopsy specimens of 4 to 6 mm of the skin were obtained from 
| mAbs and flow cytometry
Antibodies were purchased from Biolegend-anti-mouse CD3 (145- 
| Gene expression analysis
Skin bunch biopsy specimens of 4 mm were taken from affected areas of mice or 4-to 6-mm punch biopsy specimens were taken from affected areas from patients and homogenized with the use of lys- 
| Statistical analysis
Survival curves were plotted using Kaplan-Meier estimates and compared by log-rank analysis. Unpaired 2-tailed Mann-Whitney tests were used to evaluate differences in cytokine expression and cell frequencies, and ANOVA was used when comparisons were made between ≥3 groups. One-sample t tests were used to compare cytokine expression by qPCR in clinical samples. Data are given as mean ± SEM unless otherwise stated, and P < .05 was considered significant.
| RESULTS
| Donor-derived IL-22 promotes cutaneous chronic GVHD in allo-SCT recipients
Given the contrasting roles reported for IL-22 in inflammation and acute GVHD, 8,15-17 we used allo-SCT models whereby chronic GVHD was directed to an MHC disparity in WT and IL-22 −/− recipients.
Because IL-22 is known to contribute to inflammatory skin disease pathology, 11, [27] [28] [29] we used a murine model in which cutaneous chronic GVHD is induced by WT T cells, 20 and examined the effect of IL-22 deficiency in the donor graft. Here, we observed a significant reduction in overall GVHD clinical scores and a striking reduction specifically in cutaneous GVHD scores in the absence of donor IL-22 ( Figure 1A , B).
Semiquantitative histopathology of skin 35 days after transplantation also demonstrated significantly reduced cellular infiltration and inflammation equating to a reduction in cutaneous GVHD pathology in these mice ( Figure 1C, D) . IL-22 is also reported to have a dual role in airway inflammation, whereby IL-22 expression in the lung suppresses antigen-induced eosinophilic infiltration and airway inflammation.
30-32
However, IL-22 can also exacerbate asthma development in response to subcutaneous antigen sensitization. 33, 34 Therefore, we used a model of chronic GVHD that closely models the features of bronchiolitis obliterans (BO), resulting in alloantigen-induced epithelial injury, fibroproliferation, impaired pulmonary function, and lung pathology ( Figure 1E, F) . 35 Lung function studies in mice 60 days after transplantation demonstrated clear impairment in lung compliance and increased elastance and resistance in the presence of donor WT T cells ( Figure 1E ). However, IL-22 deficiency in donor T cells did not significantly alter these functional manifestations of BO. Chronic liver and lung GVHD were evident in semiquantitative histopathology assessments of tissue derived from recipients of TCR grafts, but no significant differences were observed between recipients of either WT or IL-22 −/− T cells ( Figure 1F ). These data suggest that donor-derived IL-22 plays a relatively specific role in promoting chronic GVHD in the skin late after allo-SCT.
| GVHD results in proinflammatory donor Th22 and IL-22 + Th17 differentiation
We next assessed T cell differentiation after transplantation through cytokine expression within donor T cells in multiple models of GVHD.
In both B6 → B6D2F1 and BALB/c → B6 systems, we observed IL-22 expression almost exclusively by CD4 + T cells, a minority of which coexpressed IL-17A (Figure 2A, B) . In addition, a large proportion of IL- 
| Th22 arise independently of the Th17 lineage but IL-17 promotes Th22 differentiation
Cytokine plasticity is a well-characterized feature of IL-17-producing Figure 3A ).
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Again, a distinct IL-22 + YFP − CD4 + T cell population was clearly observed in these analyses, in parallel to that seen in direct cytokine reporter mice ( Figure 2E ). While Th22 and Th17 are known to have distinct differentiation pathways (eg, differential requirements for TGF-β), both populations are reported to be dependent on IL-6.
8,10,41
We have previously demonstrated systemic IL-6 dysregulation in re- 
| Donor Th17-derived IL-22 drives skin GVHD late posttransplantation
We have previously demonstrated that in vitro polarized Th17 cells can significantly exacerbate skin GVHD, 22 were treated for 3 weeks with IL-22-blocking mAbs, which resulted in a significant reduction in skin GVHD (>day 17 P < .01; Figure 4D , E).
However, anti-IL-22 mAbs did not improve the systemic manifestations of late inflammatory chronic GVHD with no difference in overall survival between control and anti-IL-22 mAb-treated animals (data not shown).
| IL-22 and IL-17 levels are elevated in patients with cutaneous GVHD
Immunosuppression during the first 3 to 4 months after transplantation is effective in controlling most donor T cell inflammatory cytokine production; however, during the onset phase of chronic GVHD (>100 days), systemic IL-17A and IFNγ levels increase over time. 42 In a study of pediatric allo-SCT recipients, a significant correlation was observed between increased Il22 gene expression in peripheral blood mononuclear cells and active cGVHD. 44 Given this and our observations in murine models of chronic GVHD, we assessed plasma IL-22 levels in a clinical cohort after allo-SCT. We found that unlike IL-17A, 42 systemic IL-22 protein levels remained consistently low after transplantation (data not shown). To gain a better understanding of cytokine responses in GVHD target tissue, we evaluated cutaneous gene expression in patients >100 days post allo-SCT in parallel with biopsy confirmation of GVHD ( Figure 5A ). These data were compared with data for skin biopsy specimens taken from patients after autologous transplantation who do not develop GVHD ( Figure 5B ). We again observed a clear correlation between GVHD and elevated tissue cytokine transcript levels, particularly dysregulated IL-22, IL-17A, and
IFNγ. These data show striking similarities with that observed in our 
